At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
02162 KEYMED BIO-B
Closed Christmas Day 12-24 12:08:29
31.750
-0.100
-0.31%
High32.200
Low31.100
Vol1.52M
Open32.000
D1 Closing31.850
Amplitude3.45%
Mkt Cap8.88B
Tradable Cap8.88B
Total Shares279.74M
T/O47.96M
T/O Rate0.54%
Tradable Shares279.74M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
KeyMed Biosciences Announces Approval of Stapokibart for the Treatment of Chronic Rhinosinusitis With Nasal Polyposis
Institutions along with individual investors who hold considerable shares inKeymed Biosciences Inc. (HKG:2162) come under pressure; lose 7.1% of holdings value
Stapokibart Was Granted Marketing Approval From National Medical Products Administration for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults
Keymed Biosciences Inc is a China-based biotechnology company. The Company focuses on the independent discovery and development of innovative biological therapies that address underserved medical needs in the autoimmune and oncology therapeutic areas. The Company has mastered in-house drug discovery and development technologies, including an innovative antibody discovery platform and a proprietary novel T cell engager (nTCE) bispecific antibody platform. The Company has also established a fully integrated platform covering the key functions of biopharmaceutical development. The Company's main products include CM310, CM326 and CMG901.